Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?

BioNTech: The Mainz-Based Biotech Pioneer with Ambitions in Cancer Research

BioNTech shares experienced a phenomenal comeback in recent trading days, posting a weekly gain of nearly 30%. From a low of just over USD 91, the stock temporarily climbed to just under USD 116, not only approaching the magical three-digit mark again but also firmly in that range, with an after-hours price above USD 116. However, the Mainz-based company owes its recent price surge primarily to the successes of its competitors. The market is celebrating Moderna's positive Phase 3 data for skin cancer vaccines and is directly projecting this optimism onto the entire mRNA technology sector.

A look at the company's own figures, however, reveals the enormous challenges of the transition. The once-thriving COVID-19 vaccine business continues to slump, with revenue declining to just EUR 106 million in the second quarter. The bottom line for the second quarter was a net loss of EUR 820.8 million, prompting management to revise its full-year revenue forecast downward to between EUR 1.6 and 1.9 billion. Nevertheless, BioNTech has very strong financial backing, with cash and cash equivalents totaling EUR 16.6 billion.

Consequently, the investment thesis is based not only on current earnings but also on the massive oncology pipeline. Investors are expecting key clinical data from Seoul this fall, as well as progress on the promising candidate BNT323.

From a technical analysis perspective, the stock is hovering just below the key level of USD 120; a sustained break above this level would pave the way toward USD 130 and perhaps even USD 140–150 on the Nasdaq. Extremely exciting, but also speculative.

Moderna: The US Pioneer is Taking the Next Step in the Billion-Dollar mRNA Market

Moderna has caused a real sensation on the stock market and triggered a veritable surge in sentiment and hype. The catalyst for this euphoria was the spectacular results of a Phase 3 trial for the treatment of melanoma patients in collaboration with Merck. With this, the US company provided definitive proof that mRNA cancer therapies are likely no longer a pipe dream. Investors celebrated the breakthrough with a massive buying spree, catapulting the stock out of its months-long slump. A short squeeze likely did the rest, further fueling the rally. At its peak, the share gained nearly 200%.

From an operational perspective, this trial success sets the stage for a sustainable strategic realignment far removed from the declining COVID-19 business. Moderna is thus demonstrating the extremely high validity of its technology platform and is already aiming for its first market approvals in the cancer sector as early as 2027. The company is thus rapidly transforming itself from a pure pandemic beneficiary into a leading pioneer in personalized immunotherapies. Operating results are expected to improve significantly with these future revenue drivers.

For investors, Moderna currently serves as the dominant driving force and catalyst for the entire biotech sector. The valuation now reflects the immense potential lying dormant in the entire market for oncology therapies. With proof of concept in hand, Moderna may now be a candidate for many long-term investors. The path to a lasting revaluation on Wall Street thus appears clear. Analyst firms are likely to revise their estimates upward—in some cases, this has already happened. It will be interesting to see whether the stock rebounds after its brief, sharp dip.

Volatus Aerospace: Can Canada's Drone Specialist Gain Serious Momentum?

Volatus Aerospace, the Canadian specialist in unmanned aerial systems, is increasingly attracting investor attention with a series of significant milestones.

In early August, the company entered into forward-looking partnerships with Kraus Hamdani Aerospace for the K1000ULE long-endurance reconnaissance drones and with Singular Aircraft for heavy-lift firefighting drones.

Volatus is thus further expanding its position as a leading player in unmanned aviation and national security solutions in Canada. In the future, these systems will support not only wildfire suppression but also Arctic operations and defense missions.

The figures for the second quarter of 2026, released in mid-August, underscored that this strategy is beginning to bear fruit operationally. Although still at a "level with room for growth," revenue climbed significantly compared to the previous quarter, rising by an impressive 49.5% to CAD 8.4 million, driven by 59% growth in the services segment and 38% growth in equipment deliveries. Although upfront costs for the defense division weighed on quarterly profits, with cash and cash equivalents of CAD 59.2 million and working capital of CAD 63.8 million, the company is in a stronger financial position than ever before. In addition, Volatus opened a 53,000-square-foot manufacturing facility at Montreal-Mirabel Airport in June to significantly ramp up production.

From a technical analysis perspective, Volatus Aerospace shares are in an extremely exciting position and currently trading at around CAD 0.50. On the downside, solid horizontal support in the range of CAD 0.44 to CAD 0.48 provides a fairly stable technical safety net. If the share now manages to break through the key resistance levels at CAD 0.55 or CAD 0.56, it could potentially gain momentum quickly and dynamically. In this scenario, an initial target range would be at the upper trend line at CAD 0.70. Should the buying wave prove particularly strong, the bulls would quickly set their sights on the previous all-time highs in the range of CAD 0.80 to CAD 0.90. A sustained break above this level would ultimately clear the path toward the psychologically important CAD 1.00 mark.

For BioNTech, the current recovery remains primarily driven by sector optimism, while its financial recovery must patiently await a breakthrough in its own cancer pipeline. With its groundbreaking trial data, Moderna has demonstrated the technological feasibility of mRNA in oncology, reestablishing itself as a dynamic industry leader. Volatus Aerospace has laid a rock-solid foundation both operationally and financially and, from a technical analysis perspective, is on the verge of a highly exciting breakout opportunity.